Followers | 72 |
Posts | 4225 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Monday, March 11, 2024 11:33:54 AM
LSD is not shelf stable as I commented to another user. So they will apply some fancy structures to the molecules to delay decay and increase shelf life.
Want some light bedtime reading... while this predates some concepts they are likely using have a look at - Thermodynamic Considerations in the Formation of Ergot Alkaloids - https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/bit.260150116
Smart chemists read old material because in most cases it is forgotten. The team they have knows what they are doing. They understand Gibbs free energy and know its relationship with Steric hindrance to make a drug not only work as intend but increase the quality.
Why do I be the farm on MindMed? Because everyone can grown Mushrooms... you have to be clandestine to make good LSD and even better to bring something to market.
There's my Ted Talk... don't worry about the stock price. It will go far further than you can imagine. Wall Street folks are not chemists - neither are analysts... guess who is lining their pockets with shares? Those that understand what I outlined here.
If they get FDA approval. Which they will in my mind. You are holding onto a powder keg.
Recent MNMD News
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:15:11 PM
- MindMed Reports 2023 Financial Results and Business Updates • Business Wire • 02/28/2024 12:05:00 PM
- MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update • Business Wire • 02/22/2024 12:00:00 PM
- MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:24 PM
- MindMed Announces Business Update and Anticipated Milestones for 2024 • Business Wire • 01/08/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 09:59:47 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM